Actinium Pharmaceuticals logo

Actinium PharmaceuticalsNYSE American: ATNM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 December 2012

Next earnings report:

25 April 2025

Last dividends:

N/A

Next dividends:

N/A
$45.86 M
-87%vs. 3y high
34%vs. sector
-vs. 3y high
-vs. sector
-83%vs. 3y high
43%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 00:46:52 GMT
$1.47+$0.02(+1.38%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

ATNM Latest News

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
prnewswire.com18 November 2024 Sentiment: POSITIVE

-  Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia -  Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes -  Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 -  Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed or refractory acute myeloid leukemia -  Accomplished biopharma industry executive June Almenoff, M.D., Ph.D., appointed to Actinium's Board of Directors   -  Cash and cash equivalents of approximately $78.6 million as of September 30, 2024, is expected to fund operations into 2027 NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted recent regulatory and development updates for its Iomab-B, Actimab-A and Iomab-ACT ARC clinical programs as well as its financial results for the third quarter ended September 30, 2024.

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
accesswire.com03 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com27 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investors To Join An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
accesswire.com26 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com19 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
zacks.com18 October 2024 Sentiment: POSITIVE

Actinium (ATNM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The Schall Law Firm Encourages Investors To Join An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
accesswire.com18 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com15 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com13 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Possible Securities Fraud
accesswire.com12 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

What type of business is Actinium Pharmaceuticals?

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

What sector is Actinium Pharmaceuticals in?

Actinium Pharmaceuticals is in the Healthcare sector

What industry is Actinium Pharmaceuticals in?

Actinium Pharmaceuticals is in the Biotechnology industry

What country is Actinium Pharmaceuticals from?

Actinium Pharmaceuticals is headquartered in United States

When did Actinium Pharmaceuticals go public?

Actinium Pharmaceuticals initial public offering (IPO) was on 27 December 2012

What is Actinium Pharmaceuticals website?

https://www.actiniumpharma.com

Is Actinium Pharmaceuticals in the S&P 500?

No, Actinium Pharmaceuticals is not included in the S&P 500 index

Is Actinium Pharmaceuticals in the NASDAQ 100?

No, Actinium Pharmaceuticals is not included in the NASDAQ 100 index

Is Actinium Pharmaceuticals in the Dow Jones?

No, Actinium Pharmaceuticals is not included in the Dow Jones index

When was Actinium Pharmaceuticals the previous earnings report?

No data

When does Actinium Pharmaceuticals earnings report?

The next expected earnings date for Actinium Pharmaceuticals is 25 April 2025